Literature DB >> 10554522

[Multi-modal therapy concepts in gastrointestinal tumors].

M Nagel1.   

Abstract

A large variety of adjuvant and neoadjuvant treatment concepts were developed during the recent years to improve the results of gastrointestinal tumors. There exist generally accepted guidelines for adjuvant treatment of colon and rectal cancer, while for the tumors of the upper gastrointestinal tract convincing results of randomized studies are still missing. Therefore ongoing and future studies have to find out, which patients could have a benefit from multimodal therapy.

Entities:  

Mesh:

Year:  1999        PMID: 10554522     DOI: 10.1007/bf03042184

Source DB:  PubMed          Journal:  Med Klin (Munich)        ISSN: 0723-5003


  5 in total

1.  Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer.

Authors:  M J O'Connell; J A Mailliard; M J Kahn; J S Macdonald; D G Haller; R J Mayer; H S Wieand
Journal:  J Clin Oncol       Date:  1997-01       Impact factor: 44.544

2.  Five-year results of a randomized controlled trial of adjuvant chemotherapy for curatively resected colorectal carcinoma. The Colorectal Cancer Chemotherapy Study Group of Japan.

Authors: 
Journal:  Jpn J Clin Oncol       Date:  1995-06       Impact factor: 3.019

3.  Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial.

Authors:  H C Hoover; J S Brandhorst; L C Peters; M G Surdyke; Y Takeshita; J Madariaga; L R Muenz; M G Hanna
Journal:  J Clin Oncol       Date:  1993-03       Impact factor: 44.544

4.  Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer.

Authors:  C G Moertel; T R Fleming; J S Macdonald; D G Haller; J A Laurie; C M Tangen; J S Ungerleider; W A Emerson; D C Tormey; J H Glick
Journal:  J Clin Oncol       Date:  1995-12       Impact factor: 44.544

5.  Combined intraperitoneal plus intravenous chemotherapy after curative resection for colonic adenocarcinoma.

Authors:  W Scheithauer; G Kornek; H Rosen; C Sebesta; A Marcell; W Kwasny; M Karall; D Depisch
Journal:  Eur J Cancer       Date:  1995-11       Impact factor: 9.162

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.